Clinical Trials Logo

Clinical Trial Summary

The main objectives of this study are:

1. Improve genetic counseling by establishment of prevalences of each of genetic subtypes within a expanded population of patients with LCA taking into account ethnicity of families.

2. Confirm, refine or modify the genotype-phenotype correlations.

3. Edit important recommendations for:

- The clinical and paraclinical exploration of a new patient based on genotype, especially for extraocular explorations, to book at certain genetic subtypes

- Prenatal care of a couple.

- Directing families to a therapeutic protocol in progress or in development.

4. Individualize a panel of families without a mutation in the known genes and identify new genes responsible.


Clinical Trial Description

This study characterize the clinical history of the disease (age and start mode of visual disturbances, rate and mode of progress of disease), careful assessment of retina function and finally, in search of the mutations responsible for this condition.

A full ophthalmic check-up, one at the inclusion and 24 months :

1. - A genetic consultation taking account of family history and establishment of family tree with precision of geographical origin of birth of ascendants.

2. - A thorough ophthalmologic examination by a referring medical ophthalmologist, including:

2.1 - An interrogation on the development of the visual awakening since the birth and its possible disturbances.

2.2 - The search for abnormal movements of the eyeballs, and difficulties with regard to different lighting.

2.3 - Visual field evaluation Survey.

2.4 - The study of color vision.

2.5 - The search for a refractive disorder with the automatic refractometer.

2.6 - Measurement of Visual acuity for near and distance.

2.7 - Examination of the eyeball as a whole, examination of the anterior chamber of the eye by the slit lamp.

2.8 - Taking pictures of the fundus of the eye after pupillary dilation.

2.9 - An autofluorescence search using a Scanning Laser Ophthalmoscopy (SLO).

2.10 - Optical Coherence Tomography (OCT) which used to assess the thickness of each of retinal layers.

2.11 - Electrophysiological examination, Electroretinogram (ERG) that allows to record the functional value of the retina.

These two latter examinations last on average 10 minutes after dilation of the pupil.

3. - A blood sample of 10 milliliters to carry out genetic studies to identify the gene responsible for this condition and genetic counseling refined by taking account the results of this study.

Intermediate visit M12: only for patients younger than 6 years of age on inclusion. ;


Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT02970266
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase N/A
Start date September 2010
Completion date November 2016

See also
  Status Clinical Trial Phase
Completed NCT01496040 - Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65 Phase 1/Phase 2
Completed NCT00516477 - Safety Study in Subjects With Leber Congenital Amaurosis Phase 1
Active, not recruiting NCT03920007 - Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D Phase 1/Phase 2
Recruiting NCT05906953 - Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR) Phase 1/Phase 2
Active, not recruiting NCT00999609 - Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis Phase 3
Active, not recruiting NCT01208389 - Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 Phase 1/Phase 2
Terminated NCT03913130 - Extension Study to Study PQ-110-001 (NCT03140969) Phase 1/Phase 2
Recruiting NCT04855045 - An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. Phase 2/Phase 3
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Completed NCT00749957 - Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis Phase 1/Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Not yet recruiting NCT04731883 - RPE65 Gene Therapy (LX101)for Leber's Congenital Amaurosis N/A
Recruiting NCT05203939 - Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis Phase 1/Phase 2
Recruiting NCT06088992 - Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT) Early Phase 1
Recruiting NCT06064565 - Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial (LIGHT) Early Phase 1
Completed NCT00821340 - Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations Phase 1
Active, not recruiting NCT03913143 - A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) Phase 2/Phase 3
Completed NCT02781480 - Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) Phase 1/Phase 2
Completed NCT02714816 - Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65